TABLE 2.
40 approved drugs with high similarity to the DILI_PGS expression signatures with |CS| ≥ 0.60.
| Compound | Indication | CS | Hepatotoxicity risk |
|---|---|---|---|
| mifepristone | Cushing’s syndrome; diabetes mellitus; terminal pregnancy | 0.71 | Yes |
| ingenol mebutate | actinic keratosis | 0.66 | No |
| acetohexamide | diabetes mellitus | 0.66 | Yes* |
| toremifene | metastatic breast cancer | 0.66 | Yes |
| fluconazole | fungal infections | 0.64 | Yes |
| secnidazole | trichomoniasis; bacterial vaginosis | 0.64 | Yes |
| tamoxifen | metastatic breast cancer | 0.63 | Yes |
| nelfinavir | HIV | 0.63 | Yes |
| tolfenamic acid | migraine | 0.63 | Yes* |
| amsacrine | acute myeloid leukemia | 0.63 | Yes* |
| pergolide | Parkinson’s disease | 0.62 | Yes |
| enoxacin | gonorrhea; urinary tract infections | 0.62 | Yes* |
| diltiazem | hypertension; angina | 0.62 | Yes |
| clozapine | schizophrenia | 0.62 | Yes |
| rucaparib | recurrent epithelial ovarian cancer; fallopian tube cancer; primary peritoneal cancer | 0.61 | Yes |
| alectinib | non-small cell lung cancer | 0.61 | Yes |
| sirolimus | renal transplant | 0.61 | Yes |
| pirenzepine | peptic ulcer; gastric ulcer; duodenal ulcer | 0.61 | No |
| isoxsuprine | thromboangiitis obliterans; cerebrovascular insufficiency | 0.61 | No |
| cyclopenthiazide | hypertension | 0.61 | No |
| carbetocin | postpartum hemorrhage | 0.61 | No |
| fluvoxamine | depression; obsessive–compulsive disorder | 0.61 | Yes |
| fluphenazine | psychosis | 0.61 | Yes |
| aclidinium | chronic bronchitis; emphysema | 0.61 | Yes |
| vincristine | acute lymphocytic leukemia; Hodgkin lymphoma | 0.60 | Yes* |
| triflupromazine | psychosis; nausea; vomiting | 0.60 | Yes* |
| dipyridamole | postoperative thromboembolism; angina | 0.60 | Yes |
| protriptyline | depression | 0.60 | Yes |
| irinotecan | metastatic colorectal cancer | 0.60 | Yes |
| doxorubicin | disseminated neoplastic conditions | 0.60 | Yes |
| mannitol | cerebral edema | 0.60 | No |
| piperacillin | polymicrobial infections | 0.60 | Yes |
| cabozantinib | medullary thyroid cancer; renal cell carcinoma; hepatocellular carcinoma | −0.60 | Yes |
| rocuronium | general anesthesia | −0.61 | No |
| etomidate | general anesthesia | −0.62 | No |
| zileuton | asthma | −0.62 | Yes |
| guanethidine | hypertension | −0.63 | No |
| estriol | vaginitis; vulvar itching | −0.64 | No |
| doconexent | nutritional supplements | −0.65 | No |
| fostamatinib | chronic immune thrombocytopenia | −0.64 | Yes |
Note: The *representing the evidence of Hepatotoxicity risk corresponding drugs comes from literature reports.